SCHEMBL25308302

SCHEMBL25308302

C1=C(Cc2nnn[nH]2)c2ccccc2/C1=C/c1cccc(Oc2ccccc2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.36
AKR1B1 P15121 2/20 0.36
CNR1 P21554 4/20 0.36
NTRK1 P04629 1/20 0.35
MMP3 P08254 1/20 0.35
MMP13 P45452 1/20 0.35
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
CHEK1 O14757 1/20 0.34
FGFR1 P11362 1/20 0.34
KDR P35968 1/20 0.34
EPOR P19235 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
GFER P55789 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PARP1 P09874 1/20 0.34
ALOX5 P09917 1/20 0.33
ALOX5AP P20292 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30095303 1.00 HTR6 (0.36) HTR6AKR1B1CNR1NTRK1MMP3
SCHEMBL25305567 0.90 HTR6 (0.38) HTR6AKR1B1CNR1MMP3MMP13
SCHEMBL30094774 0.81 HTR6 (0.43) HTR6AKR1B1CNR1MMP3MMP13
SCHEMBL25306061 0.81 HTR6 (0.43) HTR6AKR1B1CNR1MMP3MMP13
SCHEMBL24101890 0.77 PPARG (0.50) AKR1B1NTRK1MMP3MMP13LMNA
SCHEMBL30095360 0.77 PPARG (0.50) AKR1B1NTRK1MMP3MMP13LMNA
SCHEMBL8534048 0.68 GRIN1 (0.52)
SCHEMBL25305589 0.67 RXRA (0.46) AKR1B1ALDH1A1HPGDPPARG
SCHEMBL17025836 0.65 MEN1 (0.49) HTR6AKR1B1CNR1MAPTALDH1A1
SCHEMBL25261774 0.64 RXRA (0.47) HTR6MAPTALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234909-A1 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS NUCMITO PHARMACEUTICALS CO. LTD. (CN) 2023-07-27 US claimed
CN-116472034-A Indene compound, pharmaceutical composition thereof and therapeutic application thereof 藤济(厦门)生物医药科技有限公司 2023-07-21 CN claimed
CN-117916215-A Indene compound, pharmaceutical composition thereof and therapeutic application thereof 藤济(厦门)生物医药科技有限公司 2024-04-19 CN disclosed
US-20240116845-A1 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS NUCMITO PHARMACEUTICALS CO LTD (CN) 2024-04-11 US disclosed
US-20230234909-A1 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS NUCMITO PHARMACEUTICALS CO. LTD. (CN) 2023-07-27 US disclosed
US-20230234909-A1 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS NUCMITO PHARMACEUTICALS CO. LTD. (CN) 2023-07-27 US disclosed
US-20230234909-A1 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS NUCMITO PHARMACEUTICALS CO. LTD. (CN) 2023-07-27 US disclosed
CN-116472034-A Indene compound, pharmaceutical composition thereof and therapeutic application thereof 藤济(厦门)生物医药科技有限公司 2023-07-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234909-A1 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS MMP1, IDO1, COL1A1 HTR6 3429/4885AKR1B1 921/4885CNR1 1165/4885
US-20240116845-A1 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS MMP1, IDO1, COL1A1 HTR6 3429/4885AKR1B1 921/4885CNR1 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.